Science & Technology
Thu, September 23, 2010Wed, September 22, 2010Tue, September 21, 2010Mon, September 20, 2010Sun, September 19, 2010Fri, September 17, 2010Thu, September 16, 2010Wed, September 15, 2010Tue, September 14, 2010Mon, September 13, 2010Sun, September 12, 2010Fri, September 10, 2010Thu, September 9, 2010Wed, September 8, 2010Tue, September 7, 2010Mon, September 6, 2010Sat, September 4, 2010Fri, September 3, 2010Thu, September 2, 2010Wed, September 1, 2010Clarification Regarding Diamyda?s NP2 Project
//science-technology.news-articles.net/content/2 .. arification-regarding-diamyda-s-np2-project.html
Published in Science and Technology on Monday, September 13th 2010 at 9:55 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
- Click to Lock Slider
STOCKHOLM--([ BUSINESS WIRE ])--Regulatory News:
Diamyd Medical AB (STO:DIAMB)(Pink Sheets:DMYDY):
The Company would like to clarify that at this time there are no formal partnership negotiations ongoing regarding NP2, as suggested in media. A structured out-licensing process for NP2 is intended to be initiated after results from a planned Phase II study in cancer patients are available.
Diamyd announced earlier today that to date no drug related Serious Adverse Events have been reported by any patient included in Diamyd's Phase I clinical trial investigating NP2 as a potential therapy for chronic pain. Based upon the Phase I findings to date, the company is planning a multi-center, randomized, double-blind, placebo controlled Phase II clinical trial with NP2 in the United States.
About Diamyd Medical Diamyd Medical is a Swedish diabetes company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications. The company's most advanced project is the GAD-based drug Diamyd® for type 1 diabetes. Phase III trials for this drug are in progress in both Europe and the US. In 2010 the company signed an agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, to develop and commercialize the Diamyd® diabetes therapy. In addition, the company has initiated clinical studies in the US in the area of chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has also out-licensed the use of GAD for the treatment of Parkinson's disease.
Diamyd Medical has offices in Sweden and in the US. Shares are listed on Nasdaq OMX in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL). Further information is available on the company's website: [ www.diamyd.com ].
This information is disclosed in accordance with the Swedish Securities Markets Act, the Swedish Financial Instruments Trading Act, or the requirements stated in the listing agreements.
Diamyd Medical AB (publ.) Karlavgen 108, SE-115 26 Stockholm, Sweden. Tel: +46 (0)8 6610026, Fax: +46 (0)8 661 63 68 E-mail: [ info@diamyd.com ]. VAT no: SE556530-142001.
This information was brought to you by Cision [ http://www.cisionwire.com ]